首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL20 |
| Uniprot No | Q9NYY1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-176aa |
| 氨基酸序列 | LKTLNLGSCVIATNLQEIRNGFSEIRGSVQAKDGNIDIRILRRTESLQDT KPANRCCLLRHLLRLYLDRVFKNYQTPDHYTLRKISSLANSFLTIKKDLR LCHAHMTCHCGEEAMKKYSQILSHFEKLEPQAAVVKALGELDILLQWMEE TE |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-20重组蛋白的3篇代表性文献的简要信息：
---
1. **文献名称**：*IL-20 recombinant protein promotes angiogenesis in rheumatoid arthritis*
**作者**：Chen et al. (2018)
**摘要**：该研究通过体外和动物模型证明，IL-20重组蛋白通过激活STAT3/VEGF信号通路增强血管生成，促进类风湿关节炎滑膜炎症和骨破坏，提示靶向IL-20可能成为治疗策略。
---
2. **文献名称**：*Recombinant IL-20 exacerbates psoriasis-like skin inflammation via IL-20R1/IL-20R2 heterodimer signaling*
**作者**：Wang et al. (2020)
**摘要**：研究利用银屑病小鼠模型发现，外源性IL-20重组蛋白通过结合受体IL-20R1/IL-20R2激活角质形成细胞，导致促炎因子(IL-17、TNF-α)分泌增加，加重皮肤病变。
---
3. **文献名称**：*Therapeutic potential of IL-20 blockade in hepatocellular carcinoma using recombinant soluble receptors*
**作者**：Li et al. (2021)
**摘要**：该团队开发了IL-20重组可溶性受体(sIL-20R)，证明其能竞争性抑制IL-20与肿瘤细胞表面受体结合，显著抑制肝癌小鼠模型中的肿瘤生长和转移，机制涉及抑制PI3K/AKT通路。
---
**备注**：以上文献为示例，实际引用时需核对真实存在的论文信息及原文内容。如需具体文献，建议通过PubMed或Web of Science以关键词“IL-20 recombinant protein”检索最新研究。
Interleukin-20 (IL-20) is a cytokine belonging to the IL-10 family, which plays a role in regulating inflammatory and immune responses. It was first identified in the early 2000s and is primarily produced by immune cells (e.g., monocytes, T cells) and epithelial cells. IL-20 signals through two heterodimeric receptor complexes: IL-20R1/IL-20R2 and IL-20R1/IL-22R1. activating downstream pathways like JAK-STAT, MAPK, and NF-κB. This cytokine is implicated in skin biology, angiogenesis, and tissue remodeling, with dysregulation linked to inflammatory diseases such as psoriasis, rheumatoid arthritis, and atherosclerosis.
Recombinant IL-20 protein is engineered using biotechnological platforms (e.g., E. coli or mammalian expression systems) to produce purified, bioactive forms for research and therapeutic exploration. Its recombinant version enables precise study of IL-20’s mechanisms in vitro and in vivo, including its dual role in promoting inflammation and tissue repair. Notably, IL-20 overexpression in psoriasis drives keratinocyte hyperproliferation and immune cell infiltration, while in cancer, it may enhance tumor angiogenesis or suppress progression depending on context.
Current research focuses on IL-20 as a potential therapeutic target. Neutralizing antibodies or receptor antagonists are being explored to treat chronic inflammatory conditions, while recombinant IL-20 itself is investigated for regenerative applications. Challenges include understanding its context-dependent functions and minimizing off-target effects. Despite these hurdles, IL-20 remains a promising candidate for modulating immune and tissue responses in disease.
×
